Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Anagrelide

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    24 result(s) found for: Anagrelide. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2004-004058-20 Sponsor Protocol Number: SPD422-203 Start Date*: 2006-07-06
    Sponsor Name:Shire Pharmaceutical Development Limited
    Full Title: A phase II, open-label, multicentre, pharmacokinetic, pharmacodynamic and safety study of anagrelide hydrochloride in young (18-50 years) and elderly (≥ 65 years) patients with essential thrombocyt...
    Medical condition: Xagrid is an antineoplasic indicated for the reduction of elevated platelet counts in at risk essential thrombocythaemia patients who are intolerant to their current therapy or whose elevated plate...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003410-41 Sponsor Protocol Number: AOP18007 Start Date*: 2014-01-13
    Sponsor Name:AOP Orphan Pharmaceuticals AG
    Full Title: A phase III randomized, multicenter, double-blind, active controlled study to compare the efficacy and safety of two different anagrelide formulations in patients with Essential Thrombocythemia (TE...
    Medical condition: male or female patients with confirmed diagnosis of Essential Thrombocythemia
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10015494 Essential thrombocythemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) LT (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2004-004061-15 Sponsor Protocol Number: SPD422-403 Start Date*: 2005-07-07
    Sponsor Name:Shire Pharmaceutical Development Ltd.
    Full Title: A Phase IIIb, randomised, open label study to compare the safety, efficacy and tolerability of anagrelide hydrochloride versus hydroxyurea in high-risk essential thrombocythaemia patients.
    Medical condition: Essential thrombocythaemia (ET)
    Disease: Version SOC Term Classification Code Term Level
    7.1 10015493 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IE (Completed) ES (Completed) IT (Completed) SK (Completed) CZ (Completed) SI (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-017095-24 Sponsor Protocol Number: AOP13007 Start Date*: 2010-02-17
    Sponsor Name:AOP Orphan Pharmaceuticals AG
    Full Title: A phase III, randomized, multicenter, subject- and sponsor-blinded, placebo controlled study to compare the efficacy and safety of “Anagrelide retard” versus placebo in “at risk” subjects with Esse...
    Medical condition: male and female "at risk" subjects with Essential Thrombocythaemia
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015493 Essential thrombocythaemia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) SK (Completed) SI (Completed) LT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2004-001622-24 Sponsor Protocol Number: Spirit Version 12 Start Date*: Information not available in EudraCT
    Sponsor Name:Newcastle Hospital Trust
    Full Title: Phase III,multicentre,open-label,prospective randomised trial comparing Imatinib alone at 400mg versus 800mg daily versus Imatinib 400mg daily plus PEG Interferon-alpha with newly diagnosed chronic...
    Medical condition: Chronic Myeloid Leukaemia (Chronic Phase)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2004-000874-30 Sponsor Protocol Number: AOP 03-007 Start Date*: 2004-07-12
    Sponsor Name:AOP ORPHAN PHARMACEUTICALS
    Full Title: A SINGLE BLIND, MULTI-CENTE, RANDOMIZED MULTINATIONAL PHASE III STUDY TO COMPARE THE EFFICACY AND TOLERABILITY OF ANAGRELIDE VS HYDROXYUREA IN PATIENTS WITH ESSENTIAL THROMBOCYTHAEMIA
    Medical condition: essntial thrombocythaemia
    Disease: Version SOC Term Classification Code Term Level
    6.1 10043549 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-000597-22 Sponsor Protocol Number: GIMEMACML0307 Start Date*: 2007-06-20
    Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
    Full Title: The protein tyrosine kinase inhibitor nilotinib as first-line treatment of Ph+ chronic myeloid leucemia (CML) in early chronic phase: a Phase II exploratory, multicenter study
    Medical condition: Ph+ CML in early chronic phase
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009013 Chronic myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000176-32 Sponsor Protocol Number: CGX-635-CML-202 Start Date*: 2006-09-22
    Sponsor Name:Stragen France
    Full Title: A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (Omacetaxine) (CGX-635) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) with the T315I BCR-ABL G...
    Medical condition: Chronic Myeloid Leukaemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000426-66 Sponsor Protocol Number: 29BRC18.0036 Start Date*: 2018-07-13
    Sponsor Name:CHRU de Brest
    Full Title: Aprepitant versus Hydroxyzine en association avec les traitements cytoréducteurs pour les patients avec néoplasies myéloprolifératives souffrant d’un Prurit Aquagénique Persistant.
    Medical condition: néoplasies myéloprolifératives avec Prurit Aquagénique Persistant
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10040785 Skin and subcutaneous tissue disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002132-25 Sponsor Protocol Number: 12-181 Start Date*: 2015-06-29
    Sponsor Name:University Hospital Aachen AöR, represented by the executive board, represented by the Dean of the Medical Faculty
    Full Title: RUXOlitinib versus BEst Available Therapy in patients with high-risk polycythemia vera or high-risk essential thrombocythemia – The RUXO-BEAT Trial
    Medical condition: Myeloproliferative Neoplasms (MPN): high-risk Polycythemia Vera (PV) and high-risk Essential Thrombocythemia (ET)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001789-41 Sponsor Protocol Number: ET18000120 Start Date*: 2019-07-16
    Sponsor Name:Centre Léon Bérard
    Full Title: Trial Of Imatinib After Ponatinib Induction (Tipi) - A multicentre, open label phase II trial evaluating the safety and efficacy of ponatinib induction followed by imatinib maintenance in adult pat...
    Medical condition: Patients with Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), all risk scores, ≤65 years
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-004230-40 Sponsor Protocol Number: B1871006 Start Date*: 2006-02-17
    Sponsor Name:Wyeth Pharmaceuticals Inc., a wholly owned subsidary of Pfizer Inc., 500 Arcola Road, Collegeville, PA 19426, USA
    Full Title: A Phase 1/2 Study of SKI-606 in Philadelphia Chromosme Positive Leukemias
    Medical condition: Philadelphia Chromosome positive leukemias occur as a result of a reciprocal translocation between chromosomes 9 and 22. Its most common phenotype is Chronic Myelogenous Leukemia (CML), which has ...
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004848 10034877 Philadelphia chromosome positive LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) HU (Completed) AT (Completed) FI (Completed) SE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-001486-27 Sponsor Protocol Number: 1301-LG Start Date*: 2015-05-29
    Sponsor Name:European Orgainzation for the Research and Treatment of Cancer (EORTC)
    Full Title: 10-day decitabine versus conventional chemotherapy (“3+7”) followed by allografting in AML patients ≥ 60 years: a randomized phase III study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS...
    Medical condition: Acute Myeloid Leukaemia (AML) in elderly population (equal or older than 60 years).
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    20.0 10005329 - Blood and lymphatic system disorders 10024291 Leukaemias acute myeloid HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    20.0 10005329 - Blood and lymphatic system disorders 10024324 Leukaemias HLGT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) PT (Completed) LT (Completed) SK (Completed) BG (Completed) NL (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2022-001076-34 Sponsor Protocol Number: ABNL-MARRO-001 Start Date*: 2023-06-12
    Sponsor Name:Theradex (Europe) Ltd.
    Full Title: The ABNL-MARRO 001 Study: A Phase 1/2 Study of Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes
    Medical condition: Myelodysplastic syndrome/Myeloproliferative Neoplasm Overlap Syndromes
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077465 Myeloproliferative neoplasm PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002787-25 Sponsor Protocol Number: GIMEMACML0811 Start Date*: 2011-09-21
    Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
    Full Title: The protein tyrosine kinase inhibitor nilotinib as first-line treatment of Ph+, BCR-ABL+ chronic myeloid leukemia (CML) in early chronic phase: a phase IIIb, multicenter study of complete molecular...
    Medical condition: Ph+, BCR-ABL+ chronic myeloid leukemia (CML) in early chronic phase
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10054352 Chronic phase chronic myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004974-82 Sponsor Protocol Number: 2013.837 Start Date*: 2014-04-04
    Sponsor Name:Hospices Civils de Lyon
    Full Title: PETALS study : PEgylated interferon-alpha2a and TAsigna® for first Line therapy of Philadelphia chromosome-positive chronic phase CML patientS
    Medical condition: Chronic phase chronic myeloid leukaemia with Philadelphia chromosome positive or BCR-ABL positive
    Disease: Version SOC Term Classification Code Term Level
    19.1 10022891 - Investigations 10034877 Philadelphia chromosome positive PT
    19.1 100000004864 10052065 Chronic phase chronic myeloid leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001044-54 Sponsor Protocol Number: Bosupeg Start Date*: 2018-10-04
    Sponsor Name:St Olavs Hospital -Trondheim University Hospital
    Full Title: A STUDY OF EFFICACY AND SAFETY OF LONG-ACTING LOW DOSE ROPEGINTERFERON IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH BOSUTINIB FROM DIAGNOSIS: A RANDOMIZED PROSPECTIVE TRIAL
    Medical condition: Chronic myeloid leukemia at diagnosis-chronich phase
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) FI (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-003389-42 Sponsor Protocol Number: DASA-PEGIFN Start Date*: 2013-06-26
    Sponsor Name:CHU DE POITIERS
    Full Title: A phase II study to assess the efficacy and safety of frontline combination of dasatinib (SPRYCEL®) and pegylated-interferon alpha 2b (Peg-IFNα2b) therapy in patients newly diagnosed with chronic p...
    Medical condition: Patients with newly diagnosed chronic phase Chronic Myeloid Leukemia (CP-CML), not previously treated with Tyrosine Kinase Inhibitors (TKIs). First line therapy.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10054352 Chronic phase chronic myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001286-15 Sponsor Protocol Number: CGX-635-CML-203 Start Date*: 2007-09-05
    Sponsor Name:Stragen France
    Full Title: A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (CGX-635) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) who have failed or are intolerant to t...
    Medical condition: Chronic Myeloid Leukaemia (CML)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10009015 Chronic myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) FR (Completed) GB (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002916-34 Sponsor Protocol Number: ITCC-054/AAML1921 Start Date*: 2016-06-13
    Sponsor Name:Erasmus MC
    Full Title: A Phase I/II study of Bosutinib in pediatric patients with newly diagnosed chronic phase or resistant/intolerant Ph+ Chronic Myeloid Leukemia, study ITCC-054/COG AAML1921
    Medical condition: Chronic Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10009700 CML LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) IE (Completed) DE (Ongoing) ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned) DK (Completed) CZ (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 28 23:31:01 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA